176 related articles for article (PubMed ID: 9423923)
21. Electrophysiological characterisation of the antagonist properties of two novel NMDA receptor glycine site antagonists, L-695,902 and L-701,324.
Priestley T; Laughton P; Macaulay AJ; Hill RG; Kemp JA
Neuropharmacology; 1996; 35(11):1573-81. PubMed ID: 9025105
[TBL] [Abstract][Full Text] [Related]
22. NMDA receptor activation antagonizes the NMDA antagonist-induced antianxiety effect in the elevated plus-maze test in mice.
Poleszak E; Serefko A; Szopa A; Wośko S; Dudka J; Wróbel A; Oniszczuk T; Wlaź P
Pharmacol Rep; 2013; 65(5):1124-31. PubMed ID: 24399708
[TBL] [Abstract][Full Text] [Related]
23. Effects of antagonists at the NMDA receptor complex in two models of anxiety.
Plaznik A; Palejko W; Nazar M; Jessa M
Eur Neuropsychopharmacol; 1994 Dec; 4(4):503-12. PubMed ID: 7894261
[TBL] [Abstract][Full Text] [Related]
24. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization.
Parsons CG; Danysz W; Quack G; Hartmann S; Lorenz B; Wollenburg C; Baran L; Przegalinski E; Kostowski W; Krzascik P; Chizh B; Headley PM
J Pharmacol Exp Ther; 1997 Dec; 283(3):1264-75. PubMed ID: 9400002
[TBL] [Abstract][Full Text] [Related]
25. Anxiolytic-like effects of N-methyl-D-aspartate-associated glycine receptor ligands in the rat potentiated startle test.
Anthony EW; Nevins ME
Eur J Pharmacol; 1993 Dec; 250(2):317-24. PubMed ID: 7906654
[TBL] [Abstract][Full Text] [Related]
26. Failure of glycine site NMDA receptor antagonists to protect against L-2-chloropropionic acid-induced neurotoxicity highlights the uniqueness of cerebellar NMDA receptors.
Widdowson PS; Gyte AJ; Upton R; Wyatt I
Brain Res; 1996 Nov; 738(2):236-42. PubMed ID: 8955518
[TBL] [Abstract][Full Text] [Related]
27. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization.
Parsons CG; Danysz W; Bartmann A; Spielmanns P; Frankiewicz T; Hesselink M; Eilbacher B; Quack G
Neuropharmacology; 1999 Jan; 38(1):85-108. PubMed ID: 10193901
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo.
Parsons CG; Quack G; Bresink I; Baran L; Przegalinski E; Kostowski W; Krzascik P; Hartmann S; Danysz W
Neuropharmacology; 1995 Oct; 34(10):1239-58. PubMed ID: 8570022
[TBL] [Abstract][Full Text] [Related]
29. Glycine site antagonists and partial agonists inhibit N-methyl-D-aspartate receptor-mediated [3H]arachidonic acid release in cerebellar granule cells.
Viu E; Zapata A; Capdevila JL; Fossom LH; Skolnick P; Trullas R
J Pharmacol Exp Ther; 1998 May; 285(2):527-32. PubMed ID: 9580593
[TBL] [Abstract][Full Text] [Related]
30. Low doses of the glycine/NMDA receptor antagonist R-(+)-HA-966 but not D-cycloserine induce paroxysmal activity in limbic brain regions of kindled rats.
Wlaź P; Ebert U; Löscher W
Eur J Neurosci; 1994 Nov; 6(11):1710-9. PubMed ID: 7874310
[TBL] [Abstract][Full Text] [Related]
31. Putative partial agonist 1-aminocyclopropanecarboxylic acid acts concurrently as a glycine-site agonist and a glutamate-site antagonist at N-methyl-D-aspartate receptors.
Nahum-Levy R; Fossom LH; Skolnick P; Benveniste M
Mol Pharmacol; 1999 Dec; 56(6):1207-18. PubMed ID: 10570048
[TBL] [Abstract][Full Text] [Related]
32. Glycine(B) receptor antagonists and partial agonists prevent memory deficits in inhibitory avoidance learning.
Viu E; Zapata A; Capdevila J; Skolnick P; Trullas R
Neurobiol Learn Mem; 2000 Sep; 74(2):146-60. PubMed ID: 10933900
[TBL] [Abstract][Full Text] [Related]
33. Anticonvulsant effects of eliprodil alone or combined with the glycineB receptor antagonist L-701,324 or the competitive NMDA antagonist CGP 40116 in the amygdala kindling model in rats.
Wlaź P; Ebert U; Löscher W
Neuropharmacology; 1999 Feb; 38(2):243-51. PubMed ID: 10218865
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological characterization of glycine-activated currents in HEK 293 cells expressing N-methyl-D-aspartate NR1 and NR3 subunits.
Smothers CT; Woodward JJ
J Pharmacol Exp Ther; 2007 Aug; 322(2):739-48. PubMed ID: 17502428
[TBL] [Abstract][Full Text] [Related]
35. Role of ventral hippocampal GABA(A) and NMDA receptors in the anxiolytic effect of carbamazepine in rats using the elevated plus maze test.
Rezvanfard M; Zarrindast MR; Bina P
Pharmacology; 2009; 84(6):356-66. PubMed ID: 19907194
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological evaluation of the anxiolytic-like effects of EMD 386088, a partial 5-HT6 receptor agonist, in the rat elevated plus-maze and Vogel conflict tests.
Jastrzębska-Więsek M; Siwek A; Partyka A; Kubacka M; Mogilski S; Wasik A; Kołaczkowski M; Wesołowska A
Neuropharmacology; 2014 Oct; 85():253-62. PubMed ID: 24905144
[TBL] [Abstract][Full Text] [Related]
37. Neuroprotection by novel antagonists at the NMDA receptor channel and glycineB sites.
Wenk GL; Baker LM; Stoehr JD; Hauss-Wegrzyniak B; Danysz W
Eur J Pharmacol; 1998 Apr; 347(2-3):183-7. PubMed ID: 9653879
[TBL] [Abstract][Full Text] [Related]
38. Differential effects of NMDA-receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices.
Frankiewicz T; Pilc A; Parsons CG
Neuropharmacology; 2000 Feb; 39(4):631-42. PubMed ID: 10728884
[TBL] [Abstract][Full Text] [Related]
39. Chronic treatment with antidepressants affects glycine/NMDA receptor function: behavioral evidence.
Popik P; Wróbel M; Nowak G
Neuropharmacology; 2000 Sep; 39(12):2278-87. PubMed ID: 10974311
[TBL] [Abstract][Full Text] [Related]
40. Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze.
Dunn RW; Corbett R; Fielding S
Eur J Pharmacol; 1989 Oct; 169(1):1-10. PubMed ID: 2574684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
